XOMA Royalty (XOMA) Total Current Liabilities (2010 - 2026)
XOMA Royalty (XOMA) reported Total Current Liabilities of $33.1 million for Q1 2026, up 61.87% on a YoY basis from $20.4 million in Q1 2025, and down 5.01% sequentially from $34.8 million in Q4 2025.
XOMA Royalty (XOMA) Total Current Liabilities (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Total Current Liabilities data on file, last reported at $33.1 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 61.87% year-over-year to $33.1 million; the trailing twelve-month figure through Mar 2026 stood at $33.1 million (up 61.87% YoY), and the FY2025 full-year result was $34.8 million, up 42.86% from the prior year.
- Total Current Liabilities eased to $33.1 million in Q1 2026, from $34.8 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $34.8 million in Q4 2025 to a low of $5.4 million in Q3 2022.
- A 5-year average of $16.6 million and a median of $17.1 million in 2024 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities plunged 47.42% in 2022 and jumped 185.99% in 2023, its largest moves.
- Tracing XOMA's Total Current Liabilities over 5 years: stood at $6.8 million in 2022, then jumped by 185.99% to $19.5 million in 2023, then climbed by 25.0% to $24.4 million in 2024, then jumped by 42.86% to $34.8 million in 2025, then retreated by 5.01% to $33.1 million in 2026.
- Business Quant data shows XOMA's Total Current Liabilities at $33.1 million in Q1 2026, $34.8 million in Q4 2025, and $21.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 33.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.08 Mn |
| Dec 31, 2025 | 34.82 Mn |
| Jun 30, 2025 | 21.50 Mn |
| Mar 31, 2025 | 20.43 Mn |
| Dec 31, 2024 | 24.37 Mn |
| Sep 30, 2024 | 21.13 Mn |
| Jun 30, 2024 | 18.62 Mn |
| Mar 31, 2024 | 15.54 Mn |
| Dec 31, 2023 | 19.50 Mn |
| Sep 30, 2023 | 10.33 Mn |
| Jun 30, 2023 | 7.09 Mn |
| Mar 31, 2023 | 10.09 Mn |
| Dec 31, 2022 | 6.82 Mn |
| Sep 30, 2022 | 5.43 Mn |
| Jun 30, 2022 | 8.42 Mn |
| Mar 31, 2022 | 7.89 Mn |
| Dec 31, 2021 | 12.97 Mn |
| Sep 30, 2021 | 6.51 Mn |
| Jun 30, 2021 | 6.29 Mn |
| Mar 31, 2021 | 13.11 Mn |